Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04879563
Other study ID # 875351
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2021
Est. completion date June 30, 2024

Study information

Verified date April 2024
Source Region Örebro County
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 500
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH). One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital. Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services. Inclusion Criteria (breast cancer; ORB and Uppsala): - breast cancer diagnosis - no clinical evidence of metastatic disease - able for curative treatment with surgery with or without oncological treatment. Inclusion Criteria (breast cancer; Barcelona) - prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last). Inclusion Criteria (breast cancer; CareAcross) - breast cancer diagnosis (as per self-reported) irrespective of stage and treatment. Inclusion Criteria (prostate cancer; SGHA and ORB) - proostate cancer diagnosis - no clinical evidence of metastatic disease - able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination). Inclusion Criteria (prostate cancer; CareAcross) - prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment. Exclusion Criteria (common in all study sites): - inability to give informed consent - inability / no access to smartphones, applications or internet services - patients with known medical history of allergy to the wearable material.

Study Design


Intervention

Other:
ASCAPE-based follow-up strategy
Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled. The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues.

Locations

Country Name City State
Greece Urology Department, Sismanogleio General Hospital Athens
Spain Oncology Department, Hospital Clínic de Barcelona Barcelona
Sweden Department of Oncology, Örebro University Hospital Örebro
Sweden Department of Oncology, University Hospital of Uppsala Uppsala
United Kingdom CareAcross London

Sponsors (15)

Lead Sponsor Collaborator
Region Örebro County Arthur's Legal, ATOS, CareAcross, DFKI - German Research Center for Artificial Intelligence, Faculty of Sciences, University of Novi Sad, Serbia, FORTH - Foundation for Research and Technology Hellas, Fundacio Clinic Barcelona, Fundacion iSYS, Intrasoft, National and Kapodistrian University of Athens, Greece, Siemens Corporation, Corporate Technology, Sphynx Technology Solutions AG, UBITECH, University of Patras

Countries where clinical trial is conducted

Greece,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patients' experience using ASCAPE-based follow-up Patients' experience to be followed with the help of an AI-based system per se, patients' satisfaction with this type of follow-up, potential barriers and facilitators of using wearables during follow-up, and motivation for following interventions based on AI-based follow-up At the end of intervention (month 12)
Secondary Patients' engagement to ASCAPE-based follow-up Number of questionnaires submitted per patients; total time that the patients used the wearables Every three months until the end of intervention (12 months)
Secondary Patients' adherence to AI-based proposed intervention Every three months until the end of intervention (12 months)
Secondary Assessment of health-related QoL over time Every three months until the end of intervention (12 months)
Secondary Physicians' views and experience regarding ASCAPE-based follow-up in terms of implementation into clinical practice The following aspects will be considered: improvement in patient-doctor relationship; AI-based follow-up's efficiency to capture relevant QoL issues on time; changes in management or referrals made due to AI-based predictions; usefulness of the information provided by AI-based models; acceptability of integrating AI-based follow-up into clinical practice; assessment of the time needed to use AI-based follow-up in clinical practice At the end of intervention (month 12)
Secondary Physicians' views and experience regarding ASCAPE-based follow-up in terms of interaction This outcome includes issues related to the interaction between the AI-based follow-up platform and physicians as usability, accessibility, and qualitative assessment of the interface. At the end of intervention (month 12)
Secondary Physicians' experience in using ASCAPE-based follow-up This outcome includes issues related to trustworthiness, how confident physicians are regarding the reliability of AI-based follow-up, and psychological aspects in using an AI-based platform in clinical practice as perceived substitution crisis and behavioural intention. At the end of intervention (month 12)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A

External Links